Drug Development 

Preclinical 

I'm a paragraph. Click here to add your own text and edit me. It’s easy. Just click “Edit Text” or double click me to add your own content and make changes to the font. Feel free to drag and drop me anywhere you like on your page. I’m a great place for you to tell a story and let your users know a little more about you.

 

This is a great space to write long text about your company and your services. You can use this space to go into a little more detail about your company. Talk about your team and what services you provide. Tell your visitors the story of how you came up with the idea for your business and what makes you different from your competitors.

Clinical 

I'm a paragraph. Click here to add your own text and edit me. It’s easy. Just click “Edit Text” or double click me to add your own content and make changes to the font. Feel free to drag and drop me anywhere you like on your page. I’m a great place for you to tell a story and let your users know a little more about you.

Consulting 

  • IT & Telecom

  • Communications & Entertainment

  • Marketing & Communications

  • ​Financial & Professional Services

  • Architecture

  • Design & Engineering 

  • Energy

  • Resources & Infrastructure

Specialized
Advisory
Services

I'm a paragraph. Click here to add your own text and edit me. It’s easy. Just click “Edit Text” or double click me to add your own content and make changes to the font. Feel free to drag and drop me anywhere you like on your page. I’m a great place for you to tell a story and let your users know a little more about you.

Drug-device combination therapies utilising convection-enhanced delivery (CED) are an emerging therapeutic strategy for the treatment of neurological disorders. Potent cell and gene therapies (CGTs) have shown efficacy in addressing neurological diseases in animal models, but these findings have yet to be translated into efficacious clinical therapies. A critical factor limiting the use of biologics and chemotherapeutics in the central nervous system is their inability to diffuse across the blood-brain barrier (BBB) and achieve homogeneous distribution within a targeted brain structure. In 1994, scientists discovered a solution to this problem by demonstrating how interstitial convection could homogeneously deliver therapies to large brain volumes irrespective of the molecular weight of the infused agent. When delivered via CED, the blood-brain barrier becomes advantageous to CGTs and chemotherapies as it acts to retain drugs within the central nervous system thereby reducing systemic immunogenicity and off-target side effects. While there are noteworthy advantages to CED, placing catheters into the brain is significantly more invasive than systemic delivery. At Neurochase,  interventional engineering challenges that have hampered the commercialisation of medical devices for CED. 

Translational Biomedical Research Center (TBRC)

UK HEADQUARTERS 

8 Neptune Court Vanguard Way

Ocean Park, Cardiff

South Glamorgan

Wales, CF24 5PJ

INQUIRIES

info@neurochase.com

+44 7507 158943

Media Center 

 © NEUROCHASE LIMITED
Company Number 12428919